Waypoint Bio raises $20.0M (China, May 2026)
$20.0M
$20MGenerated social card
Headline
Exclusive: Waypoint Bio raises $20M to run three CAR-T trials in China - Endpoints News
About
Waypoint Bio is a biotechnology company focused on developing innovative CAR-T therapies. The company aims to address unmet medical needs in cancer treatment through its clinical trials in China. This funding will support the execution of three CAR-T trials, highlighting the company's commitment to advancing cancer therapies.
Article summary
Exclusive: Waypoint Bio raises $20M to run three CAR-T trials in China Endpoints News
Investors
Related rounds
| Jul 01, 2026 | Cobot AI | $140.0M | Series B | China |
| Jun 24, 2026 | Tectronic Maritime Space Systems | $3.0M | — | China |
| Jun 24, 2026 | Lingxi Games | — | — | China |
| Jun 16, 2026 | SiliconFlow | $294.0M | Series B | China |